A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents

The main purpose of this study is to evaluate the safety of ramucirumab (LY3009806) in combination with other targeted agents in participants with advanced cancers.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Advanced Cancer
What the trial is testing?
Abemaciclib, Merestinib, Ramucirumab
Could I receive a Placebo?
No
Enrollment Goal
23
Trial Dates
Oct 21, 2016 - Jan 22, 2019
How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.